PA
FTK icon

PharVision Advisers’s Flotek Industries FTK Stock Holding History

PharVision Advisers’s Portfolio FTK Stock Details FTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-21,545
Closed -$315K – 798
2025
Q3 		$315K Buy
+21,545
New +$272K 0.18% 201

Other funds holding FTK

MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
DSCM
Divisadero Street Capital Management Miami, Florida $4.41B AUM 90.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

PharVision Advisers's FTK Position: Q4 2025 in Review

PharVision Advisers sold out of Flotek Industries (FTK) in Q4 2025, closing a stake of 21,545 shares — an estimated $315K sold.

PharVision Advisers first reported a position in FTK in Q3 2025 and held it in 1 quarter. The position peaked at $315K in Q3 2025. 100 funds tracked by Wall St. Rank hold FTK as of Q4 2025.

  • PharVision Advisers reported no remaining Flotek Industries position as of Q4 2025 after selling out during the quarter.
  • PharVision Advisers sold 21,545 Flotek Industries shares in Q4 2025, an estimated $315K.
  • PharVision Advisers first reported a position in Flotek Industries in Q3 2025 and held it in 1 quarter.
  • PharVision Advisers's Flotek Industries position peaked at $315K in Q3 2025.
  • 100 funds tracked by Wall St. Rank held Flotek Industries as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.